<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00833547</url>
  </required_header>
  <id_info>
    <org_study_id>Sepracor051</org_study_id>
    <nct_id>NCT00833547</nct_id>
  </id_info>
  <brief_title>Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia</brief_title>
  <official_title>Effects of Eszopiclone on Sleep-dependent Learning in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether eszopiclone will normalize sleep patterns and restore
      sleep-dependent enhancement of motor skill learning in patients with schizophrenia. The
      investigators will compare subjects taking a placebo to those taking 3 mg of eszopiclone with
      regard to: sleep architecture and sleep latency as measured by actigraphy and polysomnography
      and sleep-dependent motor skill learning.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overnight Change on Finger Tapping Task</measure>
    <time_frame>Train on Day 3 and Test on Day 4 of study (experimental nights)</time_frame>
    <description>The finger tapping task involves pressing four numerically labeled keys on a standard computer keyboard with the fingers of the left hand, repeating a five element sequence (4-1-3-2-4) &quot;as quickly and accurately as possible&quot; for 30s. During both training and test sessions, participants alternated tapping and resting for 30s for a total of 12 tapping trials. The measure was the number of correct sequences per trial. Overnight change was the percent change in correct sequences from the last three training trials to the first three test trials the following morning.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep Spindle Density During Stage 2 Sleep as Measured by Polysomnography</measure>
    <time_frame>during two nights in an inpatient Clinical Research Center</time_frame>
    <description>2 baseline nights (Days 1 &amp;2); 2 experimental nights (Days 3 &amp;4)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Eszopiclone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3mg of eszopiclone on two consecutive nights</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsule that looks identical to eszopiclone capsule on two consecutive nights</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eszopiclone</intervention_name>
    <description>3 mg of eszopiclone at bedtime on two consecutive nights</description>
    <arm_group_label>Eszopiclone</arm_group_label>
    <other_name>Lunesta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically stable outpatients with DSM-IV diagnoses of Schizophrenia

        Exclusion Criteria:

          -  History of neurologic or psychiatric disease other than schizophrenia

          -  Substance abuse or dependence within the past six months

          -  Other chronic medical conditions that affect sleep

          -  Pregnancy/breast feeding

          -  Hepatic impairment

          -  Treatment with metabolic inhibitors or inducers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dara S. Manoach, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mass General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2009</study_first_submitted>
  <study_first_submitted_qc>January 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2009</study_first_posted>
  <results_first_submitted>July 17, 2014</results_first_submitted>
  <results_first_submitted_qc>August 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2014</results_first_posted>
  <last_update_submitted>August 26, 2014</last_update_submitted>
  <last_update_submitted_qc>August 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Dara S. Manoach, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Psychology, Dept. of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>sleep</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>procedural learning</keyword>
  <keyword>motor skill</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eszopiclone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo capsules that appear identical to eszopiclone capsules on 2 consecutive nights</description>
        </group>
        <group group_id="P2">
          <title>Eszopiclone</title>
          <description>3mg of eszopiclone at bedtime for two consecutive nights</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eszopiclone</title>
          <description>3mg of eszopiclone at bedtime on 2 consecutive nights</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo capsule that looks identical to eszopiclone at bedtime on 2 consecutive nights</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="10"/>
                    <measurement group_id="B2" value="34" spread="9"/>
                    <measurement group_id="B3" value="34" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Overnight change on finger tapping task</title>
          <description>The finger tapping task involves pressing four numerically labeled keys on a standard computer keyboard with the fingers of the left hand, repeating a five element sequence (4-1-3-2-4) &quot;as quickly and accurately as possible&quot; for 30s. During both training and test sessions, participants alternated tapping and resting for 30s for a total of 12 tapping trials. The measure was the number of correct sequences per trial. Overnight change was the percent change in correct sequences from the last three training trials to the first three test trials the following morning.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" spread="19"/>
                    <measurement group_id="B2" value="-5" spread="25"/>
                    <measurement group_id="B3" value="2" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>sleep spindle density</title>
          <description>spindles per minute during Stage 2 sleep</description>
          <units>spindles per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.57" spread=".56"/>
                    <measurement group_id="B2" value="1.08" spread=".43"/>
                    <measurement group_id="B3" value="1.3" spread=".5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overnight Change on Finger Tapping Task</title>
        <description>The finger tapping task involves pressing four numerically labeled keys on a standard computer keyboard with the fingers of the left hand, repeating a five element sequence (4-1-3-2-4) &quot;as quickly and accurately as possible&quot; for 30s. During both training and test sessions, participants alternated tapping and resting for 30s for a total of 12 tapping trials. The measure was the number of correct sequences per trial. Overnight change was the percent change in correct sequences from the last three training trials to the first three test trials the following morning.</description>
        <time_frame>Train on Day 3 and Test on Day 4 of study (experimental nights)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>3mg of eszopiclone on two consecutive nights</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo capsule that looks identical to eszopiclone capsule on two consecutive nights</description>
          </group>
        </group_list>
        <measure>
          <title>Overnight Change on Finger Tapping Task</title>
          <description>The finger tapping task involves pressing four numerically labeled keys on a standard computer keyboard with the fingers of the left hand, repeating a five element sequence (4-1-3-2-4) &quot;as quickly and accurately as possible&quot; for 30s. During both training and test sessions, participants alternated tapping and resting for 30s for a total of 12 tapping trials. The measure was the number of correct sequences per trial. Overnight change was the percent change in correct sequences from the last three training trials to the first three test trials the following morning.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="25"/>
                    <measurement group_id="O2" value="2" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sleep Spindle Density During Stage 2 Sleep as Measured by Polysomnography</title>
        <description>2 baseline nights (Days 1 &amp;2); 2 experimental nights (Days 3 &amp;4)</description>
        <time_frame>during two nights in an inpatient Clinical Research Center</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>3mg of eszopiclone on two consecutive nights</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo capsule that looks identical to eszopiclone capsule on two consecutive nights</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Spindle Density During Stage 2 Sleep as Measured by Polysomnography</title>
          <description>2 baseline nights (Days 1 &amp;2); 2 experimental nights (Days 3 &amp;4)</description>
          <units>spindles per minute during Stage 2 sleep</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread=".55"/>
                    <measurement group_id="O2" value="1.07" spread=".45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Eszopiclone</title>
          <description>3mg of eszopiclone on two consecutive nights</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo capsule that looks identical to eszopiclone capsule on two consecutive nights</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dara Manoach</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-6148</phone>
      <email>dara@nmr.mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

